Each medicine is listed by its generic name, with its brand names beneath. Search with either one, or with a common misspelling. Approved medicines come first.
(known as Tenuate)
Diethylpropion is an older stimulant-type appetite suppressant tablet. The label describes it as a short-term add-on to diet, for a few weeks. It is a Schedule IV controlled drug.
Also searched as: Tenuate, diethylpropion hydrochloride
(known as Victoza, Saxenda)
Liraglutide is an earlier GLP-1 medicine given as a daily injection. Saxenda is the brand approved for weight management, and Victoza is approved for type 2 diabetes.
Also searched as: liraglutide injection, daily GLP-1 shot, liraglutide pen, lyraglutide
(known as Contrave, Mysimba)
Brands: Contrave
A daily tablet combining naltrexone, an opioid blocker, with bupropion, an antidepressant. Contrave is the FDA-approved brand.
Also searched as: naltrexone bupropion extended-release
(known as Foundayo, formerly LY3502970)
Brands: Foundayo
Orforglipron is a once-daily GLP-1 pill that is not a peptide. The FDA approved it for weight management on April 1, 2026.
Also searched as: Foundayo pill, GLP-1 pill from Lilly, LY3502970, oral GLP-1
(known as Xenical, Alli)
A capsule that blocks part of the fat you eat from being absorbed. It works in the gut, not in the brain. Xenical is the prescription brand.
Also searched as: Xenical, Alli, orlistat capsules
(known as Adipex-P, Lomaira)
An older, stimulant-type appetite suppressant taken by mouth. The label describes it as a short-term add-on to diet and exercise.
Also searched as: Adipex-P, Lomaira, phentermine hydrochloride
(known as Qsymia)
Brands: Qsymia
A once-daily capsule combining phentermine, an appetite suppressant, with topiramate, an anticonvulsant. Qsymia is the FDA-approved brand.
Also searched as: phentermine topiramate extended-release
(known as Ozempic, Wegovy, Wegovy HD, Rybelsus)
Brands: Wegovy, Wegovy HD, Wegovy pill, Ozempic, Rybelsus
Semaglutide copies the gut hormone GLP-1. It is sold as a weekly injection and, since late 2025, as a daily pill for weight management.
Also searched as: GLP-1 pill, GLP-1 shot, oral Wegovy, oral semaglutide
(known as Imcivree)
Setmelanotide (Imcivree) is a daily injection approved only for obesity caused by a few rare genetic conditions or by brain injury near the hypothalamus. It is not a general weight-loss medicine.
Also searched as: Imcivree
(known as Mounjaro, Zepbound, formerly LY3298176)
Tirzepatide switches on two gut-hormone receptors, GIP and GLP-1. It is a weekly injection approved for weight management under the brand Zepbound.
Also searched as: tirzepitide, terzepatide, tirz, GLP-1 GIP shot
CagriSema pairs the amylin analog cagrilintide with semaglutide in one weekly injection. Novo Nordisk filed it with the FDA in December 2025, and no approval is recorded yet.
Also searched as: cagrisema, cagri-sema, cagrilintide semaglutide, CagriSema FDA
Cagrilintide is a long-acting amylin analogue from Novo Nordisk. On its own it is investigational. It is also half of the CagriSema combination, which is under FDA review.
Also searched as: cagri
Eloralintide is an investigational once-weekly amylin injection from Eli Lilly. Its phase 2 trial showed up to about 20% weight loss at 48 weeks, and phase 3 trials are under way. It is not approved.
Also searched as: LY3841136, eloralintide tirzepatide
(known as MariTide, formerly AMG 133)
MariTide is an investigational Amgen injection designed to be given monthly or less often. It blocks the GIP receptor and activates the GLP-1 receptor. It is not approved.
Also searched as: MariTide, AMG 133
(formerly IBI362, LY3305677)
Mazdutide is a weekly GLP-1 and glucagon receptor injection developed by Innovent Biologics under a license from Eli Lilly. China approved it for weight management in 2025. It is not approved in the U.S.
Also searched as: IBI362, LY3305677
(formerly ALT-801)
Pemvidutide is an investigational weekly injection from Altimmune that targets GLP-1 and glucagon. Its phase 3 trial is in fatty liver disease (MASH). It is not approved.
Also searched as: ALT-801
(formerly ZP8396)
Petrelintide is an investigational once-weekly amylin analogue developed by Zealand Pharma. A phase 2 trial showed up to about 10% weight loss with mostly mild nausea, and Roche has started phase 3 trials. It is not approved.
Also searched as: ZP8396
(formerly LY3437943)
Retatrutide switches on three gut-hormone receptors: GIP, GLP-1 and glucagon. It is an investigational weekly injection from Eli Lilly and is not approved.
Also searched as: reta, LY3437943, retatrutide FDA, ritatrutide
(formerly BI 456906)
Survodutide is an investigational weekly injection from Boehringer Ingelheim that activates both the GLP-1 and glucagon receptors. Two phase 3 obesity trials are published, and it is not approved.
Also searched as: BI 456906
VK2735 is an investigational GIP and GLP-1 medicine from Viking Therapeutics, tested as a weekly injection and a daily tablet. Phase 3 is under way. It is not approved.
Also searched as: VK-2735
Zenagamtide, formerly called amycretin, is an investigational Novo Nordisk medicine that activates GLP-1 and amylin receptors from a single molecule. It has been tested as a weekly injection and a daily pill. It is not approved.
Also searched as: amycretin, NNC0487-0111
(known as Symlin)
Pramlintide is an injected amylin analog approved for adults with diabetes who use mealtime insulin. It is not approved for weight loss, though small obesity trials exist.
Also searched as: Symlin, SymlinPen, pramlintide acetate
No match. Try the generic name, or fewer letters.
Looking for a pill? Read the weight-loss pills guide. Or see every brand name matched to its generic name.
How to read the status. "Approved" refers to U.S. FDA approval and only to the use named. Each profile shows how well that status has been checked. Compounded versions are not FDA-approved products and are not listed here.